Advertisement

Inflammation

, Volume 30, Issue 1–2, pp 1–6 | Cite as

Effects of Resveratrol in Inflammatory Arthritis

  • N. Elmali
  • O. Baysal
  • A. Harma
  • I. Esenkaya
  • B. Mizrak
Article

Abstract

Summary:

Nuclear factor kappa B (NF-κB), is a pivotal transcription factor involved in the activation of the TNF-α and IL-1β genes. Activation of NF-κB in synovial cells is a feature seen in arthritis patients. Resveratrol, a polyphenolic, natural phytoalexin found with particularly high levels in grape skin and red wine is potent and specific inhibitor of TNF-α and IL-1β induced NF-κB activation. We aimed to determine the in vivo effects of intra-articular injections of resveratrol on cartilage and synovium in an experimental rabbit inflammatory arthritis model.

Materials and methods:

Arthritis was induced by intra-articular injection of three times of 50 μg lipopolysaccharide (LPS) at day 0, 4 and 8 at 4-day intervals into the knee joints of rabbits. To the test group, 10 μMol/kg resveratrol in the DMSO was injected in the knees at day 0 and then it was continued once daily for 2 weeks. To the control group the same time and amount of DMSO was injected the knees of rabbits. All rabbits were killed 1 week after the last injection and cartilage tissue and synovium were evaluated with semiquantitative scoring histologically.

Results:

According to control group in the resveratrol group, significantly decreased cartilage destruction was determined by H&E staining (p = 0.04). Loss of matrix proteoglycan content in the cartilage was much lower, as determined by safranin O staining (p = 0.03). We also observed marked synovial inflammation after intra-articular injection to control knees, but not in the resveratrol treated group knees (p = 0.01).

Conclusion:

This study suggests that intra-articular injection of resveratrol may protect cartilage against the development of experimentally induced IA.

Key words

resveratrol cartilage synovium inflammatory arthritis NF-κB 

References

  1. 1.
    Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:4025–4031.PubMedGoogle Scholar
  2. 2.
    Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187:461–468.PubMedCrossRefGoogle Scholar
  3. 3.
    Sweeney, S. E., and G. S. Firestein. 2004. Signal transduction in rheumatoid arthritis. Curr. Opin. Rheumatol. 16(3):231–237.PubMedCrossRefGoogle Scholar
  4. 4.
    Feldmann, M., F. M. Brennan, B. M. Foxwell, and R. N. Maini. 2001. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr. Dir. Autoimmun. 3:99–188.Google Scholar
  5. 5.
    Fujisawa, K., H. Aono, T. Hasunuma, K. Yamamoto, S. Mita, and K. Nishioka. 1996. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum. 39:197–203.PubMedCrossRefGoogle Scholar
  6. 6.
    Marok, R., P. G. Winyard, A. Coumbe, M. L. Kus, K. Gaffney, and S. Blades, et al. 1996. Activation of the transcription factor nuclear factor-kB in human inflamed synovial tissue. Arthritis Rheum. 39:583–591.PubMedCrossRefGoogle Scholar
  7. 7.
    Yamamoto, K., T. Arakawa, N. Ueda, and S. Yamamoto. 1995. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270(52):31315–31320 (Dec 29).PubMedCrossRefGoogle Scholar
  8. 8.
    Pope, R. M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev., Immunol. 2:527–535.CrossRefGoogle Scholar
  9. 9.
    Tak, P. P., D. M. Gerlag, K. R. Aupperle, D. A. van de Geest, M. Overbeek, and B. L. Bennett, et al. 2001. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum. 44(8):1897–1907.PubMedCrossRefGoogle Scholar
  10. 10.
    Bertelli, A. A., F. Ferrara, and G. Diana, et al. 1999. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity. Int. J. Tissue React. 21:93–104.PubMedGoogle Scholar
  11. 11.
    Soleas, G. J., E. P. Diamandis, and D. M. Goldberg. 1997. Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 11:287–313.PubMedCrossRefGoogle Scholar
  12. 12.
    Jang, M., L. Cai, G. O. Udeani, K. V. Slowing, C. F. Thomas, C. W. Beecher, H. H. Fong, N. R. Farnsworth, A. D. Kinghorn, and R. G. Mehta, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220.PubMedCrossRefGoogle Scholar
  13. 13.
    Manna, S. K., A. Mukhopadhyay, and B. B. Aggarwal. 2000. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappaB, activator protein-1 and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164:6509–6519.PubMedGoogle Scholar
  14. 14.
    Estrov, Z., S. Shishodia, S. Faderl, D. Harris, Q. Van, H. M. Kantarjian, M. Talpaz, and B. B. Aggarwal. 2003. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102(3):987–995 (Aug. 1).PubMedCrossRefGoogle Scholar
  15. 15.
    Holmes-McNary, M., and A. S. Baldwin Jr. 2000. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 60(13):3477–3483 (July 1).PubMedGoogle Scholar
  16. 16.
    Subbaramaiah, K., W. J. Chung, P. Michaluart, N. Telang, T. Tanabe, H. Inoue, M. Jang, J. M. Pezzuto, and A. J. Dannenberg. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273:21875–21882.PubMedCrossRefGoogle Scholar
  17. 17.
    Surh, Y. J., K. S. Chun, H. H. Cha, S. S. Han, Y. S. Keum, K. K. Park, and S. S. Lee. 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480–481:243–268.Google Scholar
  18. 18.
    Idogawa, H., A. Imamura, K. Matsuo, K. Yoshitake, T. Umemura, and M. Ohashi. 1998. A monoarthritis model in rabbits induced by repeated intra-articular injections of lipopolysaccharide. Int. J. Exp. Pathol. 79:93–104.PubMedCrossRefGoogle Scholar
  19. 19.
    Plater-Zyberk, C., L. A. B. Joosten, M. M. A. Helsen, P. Sattonnet-Roche, C. Siegfried1, S. Alouani, F. A. J. van de Loo, P. Graber, S. Aloni, R. Cirillo, E. Lubberts, C. A. Dinarello, W. B. van den Berg, and Y. Chvatchko. 2001. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 108(12):1825–1832.PubMedCrossRefGoogle Scholar
  20. 20.
    Joosten, L. A. B., E. Lubberts, M. M. A. Helsen, T. Saxne, C. J. J. Coenen-de Roo, D. Heinegård, and W. B. van den Berg. 1999. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 1(1):81–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Miagkov, A. V., D. V. Kovalenko, C. E. Brown, J. R. Didsbury, J. P. Cogswell, S. A. Stimpson, A. S. Baldwin, and S. S. Makarov. 1998. NF-kB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA 95:13859–13864.PubMedCrossRefGoogle Scholar
  22. 22.
    Gerlag, D. M., L. J. Ransone, D. L. Boyle, P. P. Tak, A. M. Manning, and G. S. Firestein. 2000. Effect of a T cell specific NF-kB inhibitor on in vitro cytokine production and collagen-induced arthritis. J. Immunol. 165:1652–1658.PubMedGoogle Scholar
  23. 23.
    Bondeson, J., B. Foxwell, F. Brennan, and M. Feldmann. 1999. Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl. Acad. Sci. USA 96:5668–5673.PubMedCrossRefGoogle Scholar
  24. 24.
    Martinez, J., and J. J. Moreno. 2000. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59(7):865–870.PubMedCrossRefGoogle Scholar
  25. 25.
    Bertelli, A., A. A. Bertelli, A. Gozzini, and L. Giovannini. 1998. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp. Clin. Res. 24:133–138.PubMedGoogle Scholar
  26. 26.
    Fremont, L. (2000) Biological effects of resveratrol. Life Sci. 66(8):663–673 (Jan 14).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • N. Elmali
    • 1
  • O. Baysal
    • 2
  • A. Harma
    • 1
  • I. Esenkaya
    • 1
  • B. Mizrak
    • 3
  1. 1.Department of Orthopaedics and TraumatologyInönü University Medical FacultyMalatyaTurkey
  2. 2.Department of Physical Medicine and Rehabilitation Inönü University Medical FacultyMalatyaTurkey
  3. 3.Department of PathologyInönü University Medical FacultyMalatyaTurkey

Personalised recommendations